Last reviewed · How we verify
Docosahexaenoic Acid Supplementation
At a glance
| Generic name | Docosahexaenoic Acid Supplementation |
|---|---|
| Also known as | Lifestyle intervention, Diet intervention |
| Sponsor | University of Milan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia (PHASE2)
- Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery (NA)
- Omega-3 Supplementation and Mental Health in College Students (NA)
- Long-Term Omega-3 and Omega-3 Index >8%: Effects on Physiological Recovery (NA)
- Observing Metabolism of EPA With Consideration of Genetics And Sex (PHASE4)
- Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (NA)
- Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation. (NA)
- Effects of DHA in Patients With Multiple Sclerosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docosahexaenoic Acid Supplementation CI brief — competitive landscape report
- Docosahexaenoic Acid Supplementation updates RSS · CI watch RSS
- University of Milan portfolio CI